Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 16Recruiting 11Terminated 10Active not recruiting 5Withdrawn 3Temporarily not available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Recurrence 36Colorectal Neoplasms 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 27Pancreatic Neoplasms 25Melanoma 25Lymphoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Urinary Bladder Neoplasms 17Leukemia 17Head and Neck Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

enzalutamide 2radium Ra 223 dichloride 1apalutamide 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Prostatic Neoplasms, Castration-Resistant × Clear all
NCT05191017 2022-08-05

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Nuvation Bio Inc.

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02906605 2016-11-22

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Janssen Research & Development, LLC

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡